Feature | June 01, 2015

Positive Six-Month Data Support Mitralign for Functional Mitral Regurgitation Treatment

System demonstrates significant reduction in both dimensions of the mitral annulus

Mitralign, six-month data, EuroPCR 2015, MPAS

Image courtesy of Mitralign.

June 1, 2015 — Mitralign shared six-month data on its Mitralign Percutaneous Annuloplasty System (MPAS) for treatment of functional mitral regurgitation (FMR) at EuroPCR 2015 in Paris. The prospective, multi-center, single-arm study met its safety endpoint at 30 days and its performance endpoint at six months. In the clinical study, the MPAS demonstrated a statistically significant reduction in left ventricular diameter, significant reduction of both the A-P and S-L annular dimensions, and a significant improvement of the patient’s walking distance. The Mitralign Percutaneous Annuloplasty System is not approved for sale or distribution; however it is anticipated to receive CE marking in 2015.

“The data show statistically significant progress at six months, specifically in ventricular remodeling which is one cause of patient symptoms,” said Prof. Georg Nickenig of the University of Bonn. “These encouraging data further support the use of percutaneous valve repair to treat this challenging patient population.”

In his presentation, “Evaluation of the Mitralign Percutaneous Annuloplasty System for the treatment of FMR 6 month results” Nickenig showed that the system demonstrated a significant reduction in the anterior-posterior (A-P) and septal-lateral (S-L) dimensions of the annulus. Enhanced ventricular function was demonstrated by significant improvement in left ventricular end diastolic diameter and left ventricular end diastolic and systolic volumes. All patients were on optimal medical therapy and had an average ejection fraction of 33 percent.

In other EuroPCR presentations, Prof. J. Schofer, M.D., of the Medicare Center and Department for Percutaneous Interventions of Structural Heart Disease, Albertinen Heart Center, Hamburg, discussed his successful use of the MPAS to perform a direct transcatheter annuloplasty on special access patients with tricuspid regurgitation.

For more information: www.mitralign.com

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init